Hemostemix Inc. Reminds Shareholders to Vote the WHITE Proxy in Favour of the Current Trusted Board
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 09/01/16 -- Hemostemix Inc. ("Hemostemix" or the "Company") (TSX VENTURE: HEM)(OTCQX: HMTXF) thanks shareholders for their overwhelming support for their current experienced Board and reminds all shareholders to vote their WHITE proxy by 2:00 PM (MDT) on September 6, 2016.
A group of self-interested Dissidents are attempting to ambush shareholders and take over Hemostemix'' Board. The Dissidents have NO experience in developing drugs or medical devices, nor the knowledge and understanding to take Hemostemix'' technology to the next level. Their plan is to hijack the Company and use its intellectual property for their purposes. They will derail Hemostemix off its path to success and destroy shareholder value.
Hemostemix would like to set the record straight and correct the misleading statements made by the Dissidents:
If shareholders have further questions regarding statements made by the Dissident group we encourage you to call Kingsdale Shareholder Services at 1-888-518-6832 to get the facts.
The TRUE facts:
"Hemostemix'' strengthened Board and experienced management team have a clear strategy that will lead to the creation of shareholder value. Our focus is on executing and implementing that plan to the benefit of all shareholders," said Angus Jenkins, Chairman of Hemostemix'' Board of Directors. "We encourage all shareholders to vote their WHITE proxy to support Hemostemix'' Board and ensure the progress we have achieved in bringing our landmark technology to market is not lost."
We cannot allow self-interested dissidents with NO experience to get onto the Board and derail the Company. Regardless of how many shares you own or whether you plan to attend the upcoming meeting on September 8, 2016 or not, it is imperative that you vote your WHITE proxy FOR management''s nominees.
You may vote your WHITE proxy by internet or telephone, or by signing, dating, and returning the enclosed WHITE proxy by fax to Kingsdale Shareholder Services at 1-866-545-5580 or 416-867-2271. Only your later-dated proxy will count.
Shareholders are urged to vote their WHITE proxy FOR Hemostemix'' current Board of Directors prior to the proxy cut-off at 2:00 p.m. (MDT) on September 6, 2016.
You may revoke a blue proxy already given by completing and delivering your WHITE proxy. The later dated WHITE proxy revokes any and all prior proxies given by you in connection with the Meeting.
Shareholders with questions should contact Kingsdale Shareholder Services at 1-888-518-6832 toll-free in North America, or 416-867-2272 outside North America or by email at .
Hemostemix has engaged Norton Rose Fulbright Canada LLP as their legal advisor and Kingsdale Shareholder Services and their strategic advisor and proxy solicitation agent.
ABOUT HEMOSTEMIX INC.
Hemostemix is a public clinical-stage biotechnology company that develops and commercializes innovative blood-derived cell therapies for medical conditions not adequately addressed by current treatments. It is the first clinical-stage biotech company to test a stem-cell therapy in an international, multicenter, Phase 2 clinical trial for patients with critical limb ischemia (CLI), a severe form of peripheral artery disease (PAD) caused by reduced blood flow to the legs. The Phase 2 trial targets a participant''s diseased tissue with proprietary cells grown from his or her blood that are capable of supporting the formation of new blood vessels. The company recently received FDA clearance to commence clinical trials in the United States.
Hemostemix Inc. is traded on the TSX Venture Exchange under the trading symbol HEM and on the OTCQX® Best Market under the trading symbol HMTXF. For more information, visit hemostemix.com or email .
Neither the TSX Venture Exchange Inc. nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
FORWARD-LOOKING STATEMENTS
This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential," and similar expressions, or that events or conditions "will," "would," "may," "could," or "should" occur. Although Hemostemix believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward-looking statements. Forward-looking statements are based on the beliefs, estimates, and opinions of Hemostemix management on the date such statements were made. Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events, or otherwise.
Contacts:
Hemostemix Inc.
David Berman
Chief Financial Officer
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 01.09.2016 - 06:30 Uhr
Sprache: Deutsch
News-ID 1455628
Anzahl Zeichen: 8966
contact information:
Contact person:
Town:
TORONTO, ONTARIO
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 169 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Hemostemix Inc. Reminds Shareholders to Vote the WHITE Proxy in Favour of the Current Trusted Board
"
steht unter der journalistisch-redaktionellen Verantwortung von
Hemostemix Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
